Show simple item record

dc.contributor.authorRichards, M A
dc.contributor.authorHopwood, Penelope
dc.contributor.authorRamirez, A J
dc.contributor.authorTwelves, C J
dc.contributor.authorFerguson, Janice E
dc.contributor.authorGregory, W M
dc.contributor.authorSwindell, Ric
dc.contributor.authorScrivener, W
dc.contributor.authorMiller, J
dc.contributor.authorHowell, Anthony
dc.date.accessioned2010-08-16T14:04:37Z
dc.date.available2010-08-16T14:04:37Z
dc.date.issued1992
dc.identifier.citationDoxorubicin in advanced breast cancer: influence of schedule on response, survival and quality of life. 1992, 28A (6-7):1023-8 Eur J Canceren
dc.identifier.issn0959-8049
dc.identifier.pmid1627368
dc.identifier.doi10.1016/0959-8049(92)90447-A
dc.identifier.urihttp://hdl.handle.net/10541/109628
dc.description.abstractThe influence of scheduling of doxorubicin on response, survival and quality of life was assessed in a randomised trial in patients with advanced breast cancer, none of whom had previously received cytotoxic chemotherapy for advanced disease. 28 patients received 75 mg/m2 doxorubicin every 3 weeks for four courses (arm 1) and 31 patients received 25 mg/m2 weekly for 12 courses (arm 2). Response rates and median time to progression were similar in the two arms and median survival was 8 months in both arms. However, amongst patients receiving treatment every 3 weeks, psychological distress measured using the Rotterdam symptom checklist fell significantly over the course; no such change was observed in those treated weekly. Physical symptoms related to cancer improved during treatment similarly for both groups.
dc.language.isoenen
dc.subjectBreast Canceren
dc.subjectCancer Metastasisen
dc.subjectCancer Recurrenceen
dc.subject.meshAdult
dc.subject.meshAged
dc.subject.meshBreast Neoplasms
dc.subject.meshDoxorubicin
dc.subject.meshDrug Administration Schedule
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshMiddle Aged
dc.subject.meshNeoplasm Metastasis
dc.subject.meshNeoplasm Recurrence, Local
dc.subject.meshQuality of Life
dc.subject.meshSurvival Analysis
dc.subject.meshTreatment Outcome
dc.titleDoxorubicin in advanced breast cancer: influence of schedule on response, survival and quality of life.en
dc.typeArticleen
dc.contributor.departmentImperial Cancer Research Fund, Guy's Hospital, London, U.K.en
dc.identifier.journalEuropean Journal of Canceren
html.description.abstractThe influence of scheduling of doxorubicin on response, survival and quality of life was assessed in a randomised trial in patients with advanced breast cancer, none of whom had previously received cytotoxic chemotherapy for advanced disease. 28 patients received 75 mg/m2 doxorubicin every 3 weeks for four courses (arm 1) and 31 patients received 25 mg/m2 weekly for 12 courses (arm 2). Response rates and median time to progression were similar in the two arms and median survival was 8 months in both arms. However, amongst patients receiving treatment every 3 weeks, psychological distress measured using the Rotterdam symptom checklist fell significantly over the course; no such change was observed in those treated weekly. Physical symptoms related to cancer improved during treatment similarly for both groups.


Files in this item

This item appears in the following Collection(s)

Show simple item record